Study:
A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed By DD Paclitaxel (DD AC?P); DD AC Followed By DD Paclitaxel Plus Gemcitabine (DD AC?PG)
Rationale:
Drugs used in chemotherapy, such as docetaxel, doxorubicin , cyclophosphamide,
paclitaxel, and gemcitabine work in different ways to stop tumor cells from dividing so they
stop growing or die. Giving combination chemotherapy after surgery may kill any remaining
tumor cells.
Purpose:
This randomized phase III trial is studying three different combination
chemotherapy regimens and comparing how well they work in treating women who have undergone
surgery for node-positive breast cancer.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Breast Cancer |
Drug: Cyclophosphamide
Drug: Docetaxel
Drug: Doxorubicin
Drug: Gemcitabine
Drug: Paclitaxel
Drug: Cyclophosphamide
Drug: Doxorubicin |
Phase 3 |
Verified by
National Surgical Adjuvant Breast and Bowel Project (NSABP)
May, 2012
Sponsored by: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Information provided by: National Surgical Adjuvant Breast and Bowel Project (NSABP)
ClinicalTrials.gov identifier: NCT00093795
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Community Oncology Group at Cleveland Clinic Cancer Center
Independence, Ohio 44131
United States
Sandra M. Swain, MD., Study Chair